Dispensary Dosing and Potency Guidelines for Medical Patients
Medical cannabis dosing sits at an unusual intersection: products with measurable, lab-verified potency percentages sold in a retail environment where the staff cannot legally prescribe and the customer is often managing a genuine health condition. This page covers how potency is measured and labeled, how medical patients typically navigate starting doses, and where the structural boundaries between product types, patient profiles, and state regulations actually fall. Understanding the framework helps patients ask better questions — and interpret the answers.
Definition and scope
Potency in cannabis refers to the concentration of active cannabinoids — primarily delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) — expressed as a percentage of the product's total weight or volume. Under most state dispensary lab testing requirements, a licensed third-party laboratory must verify these concentrations before any product reaches the retail floor. The result appears on the package label, giving patients a reproducible data point they can actually use.
The scope of "dosing guidance" at a dispensary is legally narrower than patients sometimes expect. Budtenders are trained retail professionals, not pharmacists — the dispensary budtender role is defined in most state frameworks as product education, not clinical recommendation. The American Academy of Cannabinoid Medicine and state health departments consistently frame dispensary-level guidance as informational only. For patients with serious underlying conditions, that distinction matters.
Potency labeling is also subject to dispensary product labeling rules that vary by state but typically require THC and CBD percentage disclosure, serving size (for edibles), and total cannabinoid content per package.
How it works
Cannabinoids interact with the endocannabinoid system through CB1 and CB2 receptors. THC produces psychoactive effects primarily through CB1 receptor binding in the brain; CBD does not produce intoxication and may modulate some of THC's effects. The ratio between the two — 1:1, 2:1 CBD:THC, and so on — is a structural variable that budtenders and patients use to position products on a spectrum from high-psychoactivity to low.
Bioavailability varies significantly by delivery method:
- Inhalation (flower, vaporizer): Onset within 2–10 minutes; peak effects at 30 minutes; duration typically 1–3 hours. Bioavailability estimated at 10–35% depending on inhalation technique (National Academies of Sciences, Engineering, and Medicine, The Health Effects of Cannabis and Cannabinoids, 2017).
- Oral/edible: Onset 30–120 minutes; duration 4–8 hours; bioavailability lower (6–20%) but more variable due to first-pass hepatic metabolism.
- Sublingual tincture: Onset 15–45 minutes; partial absorption through oral mucosa bypasses first-pass metabolism, producing faster onset than swallowed edibles.
- Topical: Localized effect; minimal systemic absorption; effectively zero psychoactivity for standard topicals (not transdermal patches).
The "start low, go slow" framework — widely referenced by state health departments including California's Department of Cannabis Control and Oregon's Oregon Health Authority — translates to a concrete starting protocol for THC-naive patients: 2.5 mg THC for oral products, with a 2-hour wait before any additional dose. For dispensary edibles, the standard single serving defined by most state regulations is 10 mg THC, meaning the recommended starting dose is one-quarter of that serving.
Flower potency in legal dispensaries has climbed over the past decade. Dispensary flower products now routinely test above 20% THC, compared to an estimated 4% average in samples analyzed by the DEA's Domestic Cannabis Eradication/Suppression Program in the 1990s. That tenfold shift makes historical intuition about cannabis strength unreliable for older patients returning after a long gap.
Common scenarios
Chronic pain patients represent the largest category of medical cannabis patients in states with robust medical programs. Patients managing neuropathic pain often benefit from balanced CBD:THC ratios — 1:1 products reduce the psychoactive burden while maintaining analgesic effect at the cannabinoid receptor level. The dispensary for chronic pain product landscape is well-developed: extended-release oral formats and high-CBD vaporizer cartridges are standard inventory at most licensed medical facilities.
Patients with anxiety or PTSD require particular caution with high-THC products. THC at doses above 10 mg can exacerbate anxiety in susceptible individuals — a dose-response relationship documented in clinical literature including work published through the National Institute on Drug Abuse. High-CBD, low-THC formulations (above 20:1 CBD:THC) are often the starting point for this population. See the dispensary for anxiety and PTSD overview for product-type breakdowns specific to this condition cluster.
Cancer patients, particularly those managing chemotherapy-induced nausea, represent a population where THC's antiemetic properties are most clinically established — the FDA approved dronabinol (synthetic THC) under NDA 18-651 specifically for this indication, which gives the mechanism regulatory standing.
First-time visitors to a medical dispensary face a specific challenge: they often arrive without any calibration point. A first-time dispensary visit typically involves a review of the patient's medical cannabis registration and condition, followed by product recommendations clustered around low-potency or balanced-ratio options.
Decision boundaries
Three variables determine the appropriate starting framework for any medical patient:
- Tolerance history — prior cannabis experience, even if distant, meaningfully changes baseline sensitivity.
- Delivery method — the same milligram dose produces different peak plasma concentrations and timelines across inhalation, oral, and sublingual routes.
- Cannabinoid ratio — not just THC percentage in isolation, but the THC-to-CBD ratio, which affects both psychoactivity and therapeutic profile.
State purchase limits at dispensaries create an indirect ceiling on titration speed — patients can only acquire a defined quantity within a given period, which naturally paces any dose escalation. In California, the daily purchase limit for medical patients is 8 ounces of dried flower equivalent.
Products at dispensary concentrates represent the high-potency end of the spectrum, with THC concentrations commonly exceeding 70–80%. These are rarely appropriate as an entry point for medical patients new to cannabis. The regulatory and safety context around concentrated products — including safety context and risk boundaries for dispensary — reflects this: most state frameworks require enhanced labeling and, in some cases, additional staff training for concentrate sales.